Share Price and Basic Stock Data
Last Updated: February 12, 2026, 9:57 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bharat Immunological & Biological Corporation Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹18.90 and a market capitalization of ₹81.8 Cr. The company has shown fluctuating revenue trends over the past few years. For instance, the reported sales for the fiscal year ending March 2023 stood at ₹45 Cr, a significant decline from ₹78 Cr in March 2022 and ₹85 Cr in March 2021. The trailing twelve months (TTM) sales have further decreased to ₹8 Cr, indicating ongoing challenges in revenue generation. Quarterly sales also reflect this downward trajectory, with the most recent quarters showing zero sales reported in June 2023 and September 2023. The company’s historical sales performance was stronger, peaking at ₹203 Cr in March 2014, but has since struggled to maintain growth. This decline in revenue is concerning and points to potential operational issues that may need addressing to return to profitability.
Profitability and Efficiency Metrics
Profitability remains a critical concern for Bharat Immunological & Biological Corporation, as evidenced by its negative net profit margins. The net profit for the fiscal year ending March 2023 was reported at ₹-17 Cr, down from ₹-9 Cr in March 2022, reflecting a consistent inability to generate profit. The company recorded an operating profit margin (OPM) of -41% for the same period, indicating significant operational inefficiencies. The interest coverage ratio (ICR) stood at -2.22x, highlighting the firm’s struggle to cover its interest obligations, which poses additional financial risks. Furthermore, return on equity (ROE) and return on capital employed (ROCE) are reported at 17.7% and 9.27%, respectively, suggesting that while there is some capital efficiency, the overall profitability remains heavily impacted by ongoing losses. The lack of positive operating profit across recent quarters underscores the urgent need for operational restructuring.
Balance Sheet Strength and Financial Ratios
The balance sheet of Bharat Immunological & Biological Corporation reflects a precarious financial position with total borrowings reported at ₹74 Cr against reserves of ₹36 Cr. The debt-to-equity ratio is at 0.79, indicating a reliance on debt financing, which could strain the company’s financial stability if revenues do not improve. The current ratio of 0.36 suggests liquidity issues, as it indicates that current liabilities exceed current assets. Additionally, the book value per share has decreased from ₹24.40 in March 2022 to ₹20.33 in March 2023, demonstrating a decline in shareholder equity. The price-to-book value ratio (P/BV) stands at 1.09x, suggesting the market values the company close to its book value, which may reflect investor skepticism regarding future growth. The overall financial ratios signal caution, emphasizing the need for the company to enhance its balance sheet resilience to regain investor confidence.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bharat Immunological & Biological Corporation shows a stable promoter holding of 59.25%, indicating strong control by the founders and management. The public holds 40.74% of the shares, with the total number of shareholders reported at 35,313 as of September 2023. This relatively high public ownership may reflect a level of investor interest, despite the company’s financial challenges. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could indicate a lack of confidence from larger institutional players, which often view financial instability as a red flag. The stability in promoter holdings alongside the declining performance metrics may raise concerns about the company’s governance and strategic direction. As the company continues to navigate its financial difficulties, maintaining investor confidence will be crucial for any potential recovery.
Outlook, Risks, and Final Insight
The outlook for Bharat Immunological & Biological Corporation hinges on its ability to address significant operational inefficiencies and improve revenue generation. Key risks include ongoing financial losses, a high reliance on debt, and potential cash flow constraints that could hinder the company’s ability to invest in growth initiatives. The pharmaceutical sector typically demands innovation and efficiency, areas where Bharat has struggled recently. However, the stability in promoter holdings could provide a foundation for potential strategic realignment. If management can implement effective operational changes and restore profitability, the company may regain traction in the market. Conversely, failure to address these issues could lead to further declines in both financial performance and investor confidence, necessitating a reevaluation of its business model to ensure long-term sustainability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 158/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,451 Cr. | 319 | 479/192 | 72.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 30.6 Cr. | 41.3 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 82.8 Cr. | 56.5 | 56.7/17.0 | 197 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,994.39 Cr | 1,109.18 | 54.25 | 201.93 | 0.36% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of Bharat Immunological & Biological Corporation Ltd
Quarterly Result
| Metric | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.36 | 25.20 | 15.62 | 14.22 | 24.70 | 17.43 | 22.04 | 10.48 | 26.48 | 0.00 | 7.65 | 0.00 | 0.00 |
| Expenses | 29.86 | 27.47 | 31.54 | 13.18 | 28.19 | 16.41 | 25.71 | 15.31 | 28.98 | 4.72 | 11.67 | 4.31 | 4.68 |
| Operating Profit | -4.50 | -2.27 | -15.92 | 1.04 | -3.49 | 1.02 | -3.67 | -4.83 | -2.50 | -4.72 | -4.02 | -4.31 | -4.68 |
| OPM % | -17.74% | -9.01% | -101.92% | 7.31% | -14.13% | 5.85% | -16.65% | -46.09% | -9.44% | -52.55% | |||
| Other Income | 0.14 | 1.20 | 9.08 | 0.25 | 0.22 | 0.12 | 0.59 | 0.14 | 0.32 | 0.10 | 0.49 | 0.10 | 0.16 |
| Interest | 1.17 | 1.30 | 1.22 | 1.16 | 1.23 | 1.54 | 1.68 | 1.58 | 1.74 | 1.67 | 2.06 | 1.72 | 2.09 |
| Depreciation | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.09 | 0.03 | 0.03 |
| Profit before tax | -5.59 | -2.43 | -8.12 | 0.07 | -4.56 | -0.44 | -4.81 | -6.31 | -3.96 | -6.33 | -5.68 | -5.96 | -6.64 |
| Tax % | -30.77% | -21.81% | -19.46% | -2,642.86% | 105.26% | -25.00% | -11.02% | -20.76% | -22.22% | -26.07% | -31.69% | -23.15% | -26.05% |
| Net Profit | -3.87 | -1.89 | -6.53 | 1.93 | -9.36 | -0.33 | -4.28 | -5.00 | -3.08 | -4.68 | -3.88 | -4.59 | -4.92 |
| EPS in Rs | -0.90 | -0.44 | -1.51 | 0.45 | -2.17 | -0.08 | -0.99 | -1.16 | -0.71 | -1.08 | -0.90 | -1.06 | -1.14 |
Last Updated: February 28, 2025, 12:58 pm
Below is a detailed analysis of the quarterly data for Bharat Immunological & Biological Corporation Ltd based on the most recent figures (Sep 2023) and their trends compared to the previous period:
- For Sales, as of Sep 2023, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2023) which recorded 0.00 Cr..
- For Expenses, as of Sep 2023, the value is 4.68 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.31 Cr. (Jun 2023) to 4.68 Cr., marking an increase of 0.37 Cr..
- For Operating Profit, as of Sep 2023, the value is -4.68 Cr.. The value appears to be declining and may need further review. It has decreased from -4.31 Cr. (Jun 2023) to -4.68 Cr., marking a decrease of 0.37 Cr..
- For OPM %, as of Sep 2023, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2023) which recorded 0.00%.
- For Other Income, as of Sep 2023, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.10 Cr. (Jun 2023) to 0.16 Cr., marking an increase of 0.06 Cr..
- For Interest, as of Sep 2023, the value is 2.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.72 Cr. (Jun 2023) to 2.09 Cr., marking an increase of 0.37 Cr..
- For Depreciation, as of Sep 2023, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2023) which recorded 0.03 Cr..
- For Profit before tax, as of Sep 2023, the value is -6.64 Cr.. The value appears to be declining and may need further review. It has decreased from -5.96 Cr. (Jun 2023) to -6.64 Cr., marking a decrease of 0.68 Cr..
- For Tax %, as of Sep 2023, the value is -26.05%. The value appears to be improving (decreasing) as expected. It has decreased from -23.15% (Jun 2023) to -26.05%, marking a decrease of 2.90%.
- For Net Profit, as of Sep 2023, the value is -4.92 Cr.. The value appears to be declining and may need further review. It has decreased from -4.59 Cr. (Jun 2023) to -4.92 Cr., marking a decrease of 0.33 Cr..
- For EPS in Rs, as of Sep 2023, the value is -1.14. The value appears to be declining and may need further review. It has decreased from -1.06 (Jun 2023) to -1.14, marking a decrease of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:04 am
| Metric | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 173 | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 45 | 8 |
| Expenses | 41 | 164 | 191 | 143 | 132 | 111 | 43 | 93 | 77 | 106 | 83 | 63 | 25 |
| Operating Profit | 6 | 9 | 12 | 3 | -4 | 13 | -8 | -9 | -10 | -21 | -5 | -18 | -18 |
| OPM % | 12% | 5% | 6% | 2% | -3% | 10% | -23% | -11% | -16% | -24% | -6% | -41% | -232% |
| Other Income | 2 | 1 | 6 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 3 | 1 |
| Interest | 0 | 2 | 6 | 1 | 6 | 4 | 1 | 2 | 5 | 5 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 6 | 7 | 11 | 2 | -9 | 9 | -8 | -7 | -14 | -24 | -10 | -23 | -25 |
| Tax % | -111% | 27% | 42% | 26% | -31% | 29% | -46% | -21% | -28% | -25% | -10% | -25% | |
| Net Profit | 13 | 5 | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 |
| EPS in Rs | 2.91 | 1.16 | 1.48 | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 | -4.18 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2012-2013 | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.54% | 20.00% | -66.67% | -400.00% | 216.67% | -157.14% | -50.00% | -66.67% | -80.00% | 50.00% | -88.89% |
| Change in YoY Net Profit Growth (%) | 0.00% | 81.54% | -86.67% | -333.33% | 616.67% | -373.81% | 107.14% | -16.67% | -13.33% | 130.00% | -138.89% |
Bharat Immunological & Biological Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | 5% |
| 3 Years: | -13% |
| TTM: | -90% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -31% |
| TTM: | -42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -10% |
| 3 Years: | -9% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | -24% |
| 3 Years: | -23% |
| Last Year: | -18% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: July 25, 2025, 1:42 pm
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| Reserves | -15 | -1 | -3 | -2 | -8 | -1 | -6 | -12 | -23 | -9 | 62 | 45 | 36 |
| Borrowings | 7 | 0 | -1 | -9 | 9 | 0 | 0 | 32 | 3 | 27 | 78 | 70 | 74 |
| Other Liabilities | 45 | 48 | 52 | 48 | 24 | 17 | 16 | 62 | 103 | 43 | 29 | 28 | 35 |
| Total Liabilities | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
| Fixed Assets | 9 | 8 | 7 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 116 | 115 | 115 |
| CWIP | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 71 | 82 | 84 | 74 | 63 | 53 | 48 | 120 | 122 | 68 | 97 | 70 | 73 |
| Total Assets | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
Below is a detailed analysis of the balance sheet data for Bharat Immunological & Biological Corporation Ltd based on the most recent figures (Sep 2023) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2023, the value is 43.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 43.00 Cr..
- For Reserves, as of Sep 2023, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Mar 2023) to 36.00 Cr., marking a decrease of 9.00 Cr..
- For Borrowings, as of Sep 2023, the value is 74.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 70.00 Cr. (Mar 2023) to 74.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2023, the value is 35.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.00 Cr. (Mar 2023) to 35.00 Cr., marking an increase of 7.00 Cr..
- For Total Liabilities, as of Sep 2023, the value is 188.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 186.00 Cr. (Mar 2023) to 188.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Sep 2023, the value is 115.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 115.00 Cr..
- For CWIP, as of Sep 2023, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 0.00 Cr..
- For Investments, as of Sep 2023, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2023, the value is 73.00 Cr.. The value appears strong and on an upward trend. It has increased from 70.00 Cr. (Mar 2023) to 73.00 Cr., marking an increase of 3.00 Cr..
- For Total Assets, as of Sep 2023, the value is 188.00 Cr.. The value appears strong and on an upward trend. It has increased from 186.00 Cr. (Mar 2023) to 188.00 Cr., marking an increase of 2.00 Cr..
However, the Borrowings (74.00 Cr.) are higher than the Reserves (36.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.00 | 9.00 | 13.00 | 12.00 | -13.00 | 13.00 | -8.00 | -41.00 | -13.00 | -48.00 | -83.00 | -88.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 209 | 2 | 47 | 34 | 37 | 19 | 167 | 318 | 96 | 0 | 5 | 114 |
| Inventory Days | 241 | 87 | 66 | 84 | 77 | 2 | 23 | 67 | 308 | 56 | 202 | 13 |
| Days Payable | 316 | 99 | 70 | 103 | 26 | 1 | 6 | 204 | 259 | 61 | 5 | 4 |
| Cash Conversion Cycle | 134 | -9 | 43 | 16 | 88 | 19 | 185 | 181 | 145 | -5 | 203 | 122 |
| Working Capital Days | -20 | -20 | 21 | 20 | 28 | -19 | 59 | 10 | -108 | -174 | -227 | -549 |
| ROCE % | 20% | 23% | 42% | 9% | -8% | 31% | -18% | -11% | -22% | -46% | -3% | -9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 23 | Mar 22 | Mar 21 | Mar 20 | Mar 19 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.95 | -2.03 | -4.19 | -2.36 | -1.57 |
| Diluted EPS (Rs.) | -3.95 | -2.03 | -4.19 | -2.36 | -1.57 |
| Cash EPS (Rs.) | -3.92 | -1.98 | -4.14 | -2.31 | -1.28 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.33 | 24.40 | 7.88 | 4.74 | 7.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.33 | 24.40 | 7.88 | 4.74 | 7.10 |
| Revenue From Operations / Share (Rs.) | 10.33 | 18.15 | 19.76 | 15.48 | 19.37 |
| PBDIT / Share (Rs.) | -3.63 | -0.89 | -4.45 | -2.14 | -1.18 |
| PBIT / Share (Rs.) | -3.66 | -0.94 | -4.50 | -2.19 | -1.24 |
| PBT / Share (Rs.) | -5.29 | -2.24 | -5.61 | -3.29 | -1.71 |
| Net Profit / Share (Rs.) | -3.95 | -2.03 | -4.19 | -2.36 | -1.34 |
| PBDIT Margin (%) | -35.11 | -4.95 | -22.49 | -13.80 | -6.08 |
| PBIT Margin (%) | -35.44 | -5.22 | -22.76 | -14.15 | -6.41 |
| PBT Margin (%) | -51.22 | -12.35 | -28.36 | -21.25 | -8.81 |
| Net Profit Margin (%) | -38.23 | -11.16 | -21.22 | -15.27 | -6.92 |
| Return on Networth / Equity (%) | -19.42 | -8.30 | -53.20 | -49.87 | -18.88 |
| Return on Capital Employeed (%) | -16.78 | -3.67 | -48.70 | -36.22 | -14.71 |
| Return On Assets (%) | -9.18 | -4.11 | -17.41 | -8.05 | -4.63 |
| Total Debt / Equity (X) | 0.79 | 0.73 | 0.80 | 0.14 | 1.05 |
| Asset Turnover Ratio (%) | 0.22 | 0.49 | 0.73 | 0.53 | 0.93 |
| Current Ratio (X) | 0.36 | 0.64 | 0.52 | 0.92 | 1.12 |
| Quick Ratio (X) | 0.34 | 0.28 | 0.31 | 0.41 | 0.95 |
| Inventory Turnover Ratio (X) | 1.75 | 2.38 | 1.87 | 2.08 | 10.43 |
| Interest Coverage Ratio (X) | -2.22 | -0.69 | -4.02 | -1.95 | -2.54 |
| Interest Coverage Ratio (Post Tax) (X) | -1.42 | -0.56 | -2.79 | -1.15 | -1.89 |
| Enterprise Value (Cr.) | 157.30 | 186.21 | 213.23 | 16.07 | 57.50 |
| EV / Net Operating Revenue (X) | 3.53 | 2.38 | 2.50 | 0.24 | 0.68 |
| EV / EBITDA (X) | -10.04 | -47.96 | -11.11 | -1.74 | -11.29 |
| MarketCap / Net Operating Revenue (X) | 2.15 | 1.55 | 2.30 | 0.37 | 0.39 |
| Price / BV (X) | 1.09 | 1.15 | 5.77 | 1.23 | 1.08 |
| Price / Net Operating Revenue (X) | 2.15 | 1.55 | 2.30 | 0.37 | 0.39 |
| EarningsYield | -0.17 | -0.07 | -0.09 | -0.40 | -0.17 |
After reviewing the key financial ratios for Bharat Immunological & Biological Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 23, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 22) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 23, the value is -3.95. This value is below the healthy minimum of 5. It has decreased from -2.03 (Mar 22) to -3.95, marking a decrease of 1.92.
- For Diluted EPS (Rs.), as of Mar 23, the value is -3.95. This value is below the healthy minimum of 5. It has decreased from -2.03 (Mar 22) to -3.95, marking a decrease of 1.92.
- For Cash EPS (Rs.), as of Mar 23, the value is -3.92. This value is below the healthy minimum of 3. It has decreased from -1.98 (Mar 22) to -3.92, marking a decrease of 1.94.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 23, the value is 20.33. It has decreased from 24.40 (Mar 22) to 20.33, marking a decrease of 4.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 23, the value is 20.33. It has decreased from 24.40 (Mar 22) to 20.33, marking a decrease of 4.07.
- For Revenue From Operations / Share (Rs.), as of Mar 23, the value is 10.33. It has decreased from 18.15 (Mar 22) to 10.33, marking a decrease of 7.82.
- For PBDIT / Share (Rs.), as of Mar 23, the value is -3.63. This value is below the healthy minimum of 2. It has decreased from -0.89 (Mar 22) to -3.63, marking a decrease of 2.74.
- For PBIT / Share (Rs.), as of Mar 23, the value is -3.66. This value is below the healthy minimum of 0. It has decreased from -0.94 (Mar 22) to -3.66, marking a decrease of 2.72.
- For PBT / Share (Rs.), as of Mar 23, the value is -5.29. This value is below the healthy minimum of 0. It has decreased from -2.24 (Mar 22) to -5.29, marking a decrease of 3.05.
- For Net Profit / Share (Rs.), as of Mar 23, the value is -3.95. This value is below the healthy minimum of 2. It has decreased from -2.03 (Mar 22) to -3.95, marking a decrease of 1.92.
- For PBDIT Margin (%), as of Mar 23, the value is -35.11. This value is below the healthy minimum of 10. It has decreased from -4.95 (Mar 22) to -35.11, marking a decrease of 30.16.
- For PBIT Margin (%), as of Mar 23, the value is -35.44. This value is below the healthy minimum of 10. It has decreased from -5.22 (Mar 22) to -35.44, marking a decrease of 30.22.
- For PBT Margin (%), as of Mar 23, the value is -51.22. This value is below the healthy minimum of 10. It has decreased from -12.35 (Mar 22) to -51.22, marking a decrease of 38.87.
- For Net Profit Margin (%), as of Mar 23, the value is -38.23. This value is below the healthy minimum of 5. It has decreased from -11.16 (Mar 22) to -38.23, marking a decrease of 27.07.
- For Return on Networth / Equity (%), as of Mar 23, the value is -19.42. This value is below the healthy minimum of 15. It has decreased from -8.30 (Mar 22) to -19.42, marking a decrease of 11.12.
- For Return on Capital Employeed (%), as of Mar 23, the value is -16.78. This value is below the healthy minimum of 10. It has decreased from -3.67 (Mar 22) to -16.78, marking a decrease of 13.11.
- For Return On Assets (%), as of Mar 23, the value is -9.18. This value is below the healthy minimum of 5. It has decreased from -4.11 (Mar 22) to -9.18, marking a decrease of 5.07.
- For Total Debt / Equity (X), as of Mar 23, the value is 0.79. This value is within the healthy range. It has increased from 0.73 (Mar 22) to 0.79, marking an increase of 0.06.
- For Asset Turnover Ratio (%), as of Mar 23, the value is 0.22. It has decreased from 0.49 (Mar 22) to 0.22, marking a decrease of 0.27.
- For Current Ratio (X), as of Mar 23, the value is 0.36. This value is below the healthy minimum of 1.5. It has decreased from 0.64 (Mar 22) to 0.36, marking a decrease of 0.28.
- For Quick Ratio (X), as of Mar 23, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.28 (Mar 22) to 0.34, marking an increase of 0.06.
- For Inventory Turnover Ratio (X), as of Mar 23, the value is 1.75. This value is below the healthy minimum of 4. It has decreased from 2.38 (Mar 22) to 1.75, marking a decrease of 0.63.
- For Interest Coverage Ratio (X), as of Mar 23, the value is -2.22. This value is below the healthy minimum of 3. It has decreased from -0.69 (Mar 22) to -2.22, marking a decrease of 1.53.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 23, the value is -1.42. This value is below the healthy minimum of 3. It has decreased from -0.56 (Mar 22) to -1.42, marking a decrease of 0.86.
- For Enterprise Value (Cr.), as of Mar 23, the value is 157.30. It has decreased from 186.21 (Mar 22) to 157.30, marking a decrease of 28.91.
- For EV / Net Operating Revenue (X), as of Mar 23, the value is 3.53. This value exceeds the healthy maximum of 3. It has increased from 2.38 (Mar 22) to 3.53, marking an increase of 1.15.
- For EV / EBITDA (X), as of Mar 23, the value is -10.04. This value is below the healthy minimum of 5. It has increased from -47.96 (Mar 22) to -10.04, marking an increase of 37.92.
- For MarketCap / Net Operating Revenue (X), as of Mar 23, the value is 2.15. This value is within the healthy range. It has increased from 1.55 (Mar 22) to 2.15, marking an increase of 0.60.
- For Price / BV (X), as of Mar 23, the value is 1.09. This value is within the healthy range. It has decreased from 1.15 (Mar 22) to 1.09, marking a decrease of 0.06.
- For Price / Net Operating Revenue (X), as of Mar 23, the value is 2.15. This value is within the healthy range. It has increased from 1.55 (Mar 22) to 2.15, marking an increase of 0.60.
- For EarningsYield, as of Mar 23, the value is -0.17. This value is below the healthy minimum of 5. It has decreased from -0.07 (Mar 22) to -0.17, marking a decrease of 0.10.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bharat Immunological & Biological Corporation Ltd:
- Net Profit Margin: -38.23%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -16.78% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -19.42% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.34
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.79
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -38.23%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | BIBCOL, OPV Plant, Village Chola, Bulandshahar Dist Uttar Pradesh 203203 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Y K Gupta | Chairman |
| Dr. Sanjay Kumar Mishra | Managing Director |
| Dr. Alka Sharma | Director |
| Dr. Mohd Aslam | Director |
| Mr. Roshan Lal | Director |
| Dr. Sudhanshu Vrati | Director |
| Dr. Madhu Dikshit | Director |
FAQ
What is the intrinsic value of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd's intrinsic value (as of 12 February 2026) is ₹32.05 which is 70.48% higher the current market price of ₹18.80, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹81.3 Cr. market cap, FY2025-2026 high/low of ₹28.8/16.6, reserves of ₹36 Cr, and liabilities of ₹188 Cr.
What is the Market Cap of Bharat Immunological & Biological Corporation Ltd?
The Market Cap of Bharat Immunological & Biological Corporation Ltd is 81.3 Cr..
What is the current Stock Price of Bharat Immunological & Biological Corporation Ltd as on 12 February 2026?
The current stock price of Bharat Immunological & Biological Corporation Ltd as on 12 February 2026 is ₹18.8.
What is the High / Low of Bharat Immunological & Biological Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bharat Immunological & Biological Corporation Ltd stocks is ₹28.8/16.6.
What is the Stock P/E of Bharat Immunological & Biological Corporation Ltd?
The Stock P/E of Bharat Immunological & Biological Corporation Ltd is .
What is the Book Value of Bharat Immunological & Biological Corporation Ltd?
The Book Value of Bharat Immunological & Biological Corporation Ltd is 18.2.
What is the Dividend Yield of Bharat Immunological & Biological Corporation Ltd?
The Dividend Yield of Bharat Immunological & Biological Corporation Ltd is 0.00 %.
What is the ROCE of Bharat Immunological & Biological Corporation Ltd?
The ROCE of Bharat Immunological & Biological Corporation Ltd is 9.27 %.
What is the ROE of Bharat Immunological & Biological Corporation Ltd?
The ROE of Bharat Immunological & Biological Corporation Ltd is 17.7 %.
What is the Face Value of Bharat Immunological & Biological Corporation Ltd?
The Face Value of Bharat Immunological & Biological Corporation Ltd is 10.0.